We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We study the Cauchy problem on the real line for the nonlocal Fisher-KPP equation in one spatial dimension,where 
\begin{equation*} u_t = D u_{xx} + u(1-\phi *u), \end{equation*}
$\phi *u$ is a spatial convolution with the top hat kernel, 
$\phi (y) \equiv H\left (\frac{1}{4}-y^2\right )$. After observing that the problem is globally well-posed, we demonstrate that positive, spatially periodic solutions bifurcate from the spatially uniform steady state solution 
$u=1$ as the diffusivity, 
$D$, decreases through 
$\Delta _1 \approx 0.00297$ (the exact value is determined in Section 3). We explicitly construct these spatially periodic solutions as uniformly valid asymptotic approximations for 
$D \ll 1$, over one wavelength, via the method of matched asymptotic expansions. These consist, at leading order, of regularly spaced, compactly supported regions with width of 
$O(1)$ where 
$u=O(1)$, separated by regions where 
$u$ is exponentially small at leading order as 
$D \to 0^+$. From numerical solutions, we find that for 
$D \geq \Delta _1$, permanent form travelling waves, with minimum wavespeed, 
$2 \sqrt{D}$, are generated, whilst for 
$0 \lt D \lt \Delta _1$, the wavefronts generated separate the regions where 
$u=0$ from a region where a steady periodic solution is created via a distinct periodic shedding mechanism acting immediately to the rear of the advancing front, with this mechanism becoming more pronounced with decreasing 
$D$. The structure of these transitional travelling wave forms is examined in some detail.
In order to study the structure and temperature distribution within high-mass star-forming clumps, we employed the Australia Telescope Compact Array to image the 
$\mathrm{NH}_3$ (J,K) = (1,1) through (6,6) and the (2,1) inversion transitions, the 
$\mathrm{H}_2\mathrm{O}$ 
$6_{16}$-
$5_{23}$ maser line at 22.23508 GHz, several 
$\mathrm{CH}_3\mathrm{OH}$ lines and hydrogen and helium recombination lines. In addition, 22- and 24-GHz radio continuum emission was also imaged.
The 
$\mathrm{NH}_3$ lines probe the optical depth and gas temperature of compact structures within the clumps. The 
$\mathrm{H}_2\mathrm{O}$ maser pinpoints the location of shocked gas associated with star formation. The recombination lines and the continuum emission trace the ionised gas associated with hot OB stars. The paper describes the data and presents sample images and spectra towards select clumps. The technique for estimating gas temperature from 
$\mathrm{NH}_3$ line ratios is described. The data show widespread hyperfine intensity anomalies in the 
$\mathrm{NH}_3$ (1,1) images, an indicator of non-LTE 
$\mathrm{NH}_3$ excitation. We also identify several new 
$\mathrm{NH}_3$ (3,3) masers associated with shocked gas. Towards AGAL328.809+00.632, the 
$\mathrm{H}_2\mathrm{O}$ 
$6_{16}$-
$5_{23}$ line, normally seen as a maser, is instead seen as a thermally excited absorption feature against a strong background continuum. The data products are described in detail.
Introduction: The organizational readiness for change assessment survey (ORCA) is a tool to assess a site’s readiness for implementation and identify barriers to change. As the “Kicking CAUTI” antibiotic stewardship intervention rolled out on a national scale, we administered ORCA surveys to participating sites to capture baseline actionable information about differences among sites, to inform implementation. Methods: ORCA surveys were distributed by email to prescribing providers, nurses, pharmacists, infection preventionists, and quality managers at 40 participating VA Hospitals. VA hospital sites who submitted three or more surveys and their complexity level (measured as Level 1 (highest)-3) were included in the analysis. The highest complexity level facilities are those with the largest patient volume/risk, teaching and research, along with the largest number of physician specialists and contain at least five ICUs. Mean Likert scores were calculated for each of the 7 ORCA subscales on a scale of 1-5 (5 highest), and the mean of the 7 subscales was the overall ORCA score for a site. Non-parametric testing was performed comparing overall ORCA and each subscale based on complexity. Results: Among the participating sites, 30/40 (75%) completed at least three surveys, with a total of 202 surveys included for analysis, with 82% of surveys coming from higher complexity centers (Level 1). The highest ranked ORCA domain was the evidence subscale (measures perceived strength of evidence), mean 4.2, (SD 0.7). The lowest ranked ORCA domain across sites was resources (available to facilitate implementation), mean 3.3 (SD 0.9). Higher complexity centers had a significantly higher overall ORCA score than lower complexity centers (Level 1 or 2 vs. Level 3, p= 0.02). This difference was driven by the subscales evidence (p < 0 .01), leadership (p =0.05), measurement (p= 0.06), and resources (p=0.07) all being higher in the higher complexity facilities (Figure 1). Two of the categories (leadership and measurement) pertain to an organization’s leaders ability to create an environment for change to occur as well as promoting team building. Conclusions: The lowest scoring ORCA domain across all sites was the respondents’ perception of resources (staff, training) available for achieving change. Perceived resources were also lower in lower complexity sites, implying that medical centers of lower complexity may have higher barriers when implementing an antimicrobial stewardship intervention. This finding highlights the benefit of a national stewardship campaign that provides support to lower complexity medical centers that may not otherwise receive targeted training and support for their efforts.
Disclosure: Barbara Trautner: Stock: Abbvie--sold in December 2023; Abbott Laboratories--sold in December 2023; -Bristol Myers Squibb--sold in December 2023; Pfizer--sold in December 2023; Consultant--Phiogen--consultant. Contracted research through NIAID for STRIVE trial, currently testing Shionogi product; Contracted research--Peptilogics; Contracted research—Genentech
